Contraception Clinical Trial
Official title:
SpeakOut: Empowering Teen to Teen Social Communication About Highly Effective Contraception (Also Known As: The Share Health Study: Teen Social Connections and Health)
Verified date | November 2018 |
Source | University of California, San Francisco |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to determine whether delivery of SpeakOut, a behavioral
intervention to increase social communication about long-acting reversible contraceptive
(LARC) methods among adolescents, is associated with increased uptake of LARC methods among
the social contacts of SpeakOut recipients.
The investigators will conduct a cluster randomized controlled trial of SpeakOut with
adolescent LARC users and their female peers. Over three years, SpeakOut will be implemented
in eight partner clinics. IUD and implant users aged 15 to 19 who attend appointments at
participating clinics will be invited to enroll in the evaluation study as "primary"
participants and receive either SpeakOut or a control intervention about alcohol use. The
social contacts of primary participants will be asked to enroll in the study as "secondary"
participants. The study's primary outcome will be the proportion of sexually-active secondary
participants who initiate use of a LARC method within 9 months of study enrollment.
Status | Completed |
Enrollment | 207 |
Est. completion date | June 21, 2018 |
Est. primary completion date | June 21, 2018 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 15 Years to 19 Years |
Eligibility |
Primary Participant Inclusion Criteria: - Able to speak and read English or Spanish easily - Uses an IUD or implant for birth control, or will get one of these methods inserted at an appointment on the day of enrollment - Is comfortable with close friend knowing that they use an IUD or implant - Can think of at least one friend or family member they would be comfortable asking to join a study about health topics like birth control and alcohol use Primary Participant Exclusion Criteria: - Previous enrollment as a primary or secondary participant in the study - Pregnant at baseline - Plan to get their IUD or implant removed at their visit and not replacing it with another LARC Secondary Participant Inclusion Criteria: - Able to speak and read English or Spanish easily - Was listed as a social contact by a primary participant at enrollment, and can name that primary participant at screening - Lives in California Secondary Participant Exclusion Criteria: - Pregnant at baseline - Previous enrollment as a primary or secondary participant in the study |
Country | Name | City | State |
---|---|---|---|
United States | University of California, San Francisco | Davis | California |
United States | University of Southern California Keck School of Medicine | Los Angeles | California |
Lead Sponsor | Collaborator |
---|---|
University of California, San Francisco | University of California, Davis, University of Southern California |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Contraceptive attitudes | Participants' attitudes towards various contraceptive methods, reported in global attitudinal scales in surveys, scored from 0-10. | 3 months and 9 months post-enrollment | |
Primary | Initiation of a LARC method among secondary participants | Self-reported measure of current contraceptive use in secondary participants not using IUD or implant at baseline. Will be examined among sexually active secondary participants, as well as all secondary participants regardless of sexual activity. | 3 months and 9 months post-enrollment | |
Secondary | Initiation of cluster primary participant's LARC method among secondary participants | Self-reported measure of current contraceptive use in secondary participants not using IUD or implant at baseline. Will be examined among sexually active secondary participants, as well as all secondary participants regardless of sexual activity. Outcome will also be examined separately by LARC method, i.e. implant initiation among all secondary participants not using an implant at baseline (even if they used an IUD at baseline) if the primary participant was an implant user, as well as IUD initiation among all secondary participants not using an IUD at baseline (even if they used an implant) if the primary participant was an IUD user. | 3 months and 9 months post-enrollment | |
Secondary | Positive social communication about LARC method between primary and secondary participants | Self-reported measures of discussion about contraceptive methods with primary participant, in secondary participant follow-up surveys, and 5-point likert scale measures of agreement/disagreement with statements of positive and negative content of discussion. | 3 months and 9 months post-enrollment | |
Secondary | Knowledge of cluster primary participant's LARC method among secondary participants | Secondary participants' accurate knowledge of features of their cluster primary participant's LARC method. In baseline and follow-up surveys, secondary participants will be asked to report whether or not they have ever heard of the method. If they have heard of the method in follow-up surveys, they will be asked to report on a 4-point Likert scale their self-perceived knowledge of the method. They will also be asked to answer a set of true/false/don't know knowledge items on the method's features derived from the Guttmacher Institute's Survey of Young Adults ("Fogzone" survey) and National Survey of Reproductive and Contraceptive Knowledge, as well as an item on the relative effectiveness of the method in relation to birth control pills. | 3 months and 9 months post-enrollment | |
Secondary | Positive attitudes towards cluster primary participant's LARC method among secondary participants | Self-reported global attitudinal scales of contraceptive methods in secondary participant baseline and follow-up surveys, scored from 0-10. | 3 months and 9 months post-enrollment | |
Secondary | Diagnosis of sexually transmitted infection among secondary participants | Diagnosis of a sexually transmitted infection (chlamydia, gonorrhea, trichomoniasis [or trich], or other). Measured via self-report in secondary participant follow-up surveys (binary yes/no measure of diagnosis, and measure regarding which STI they were diagnosed with). | 3 months and 9 months post-enrollment | |
Secondary | Condom use at last sexual intercourse among sexually active secondary participants | Self-reported in secondary participant baseline and follow-up surveys with standardized question from the Office of Adolescent Health in the Department of Health and Human Services. | 3 months and 9 months post-enrollment | |
Secondary | Initiation of sexual activity among secondary participants | Self-reported measure of ever having had sexual intercourse (standardized OAH measure) in secondary participant baseline and follow-up surveys among those who had not had sexual intercourse prior to enrollment. | 3 months and 9 months post-enrollment | |
Secondary | Pregnancy among secondary participants | Self-reported measure of interval pregnancy (standardized OAH measure) in secondary participant follow-up surveys. | 3 months and 9 months post-enrollment | |
Secondary | Continuation of LARC method among primary participants | Self-reported measure of current contraceptive method use in primary participant follow-up surveys. Also assessed using claims data. | 3 months and 9 months post-enrollment | |
Secondary | Initiation of social communication about LARC method among primary participants | Primary participants' report of social communication about their LARC method, as well as the number of social contacts they talked to about their LARC method. Self-reported in measures assessing discussion about contraceptive methods with people they know generally and social contacts they listed at baseline specifically in primary participant surveys. | 3 months and 9 months post-enrollment | |
Secondary | Knowledge of LARC method among primary participants | Primary participants' accurate knowledge of their chosen LARC method. In follow-up surveys, they will be asked to report on a 4-point Likert scale their self-perceived knowledge of the method. They will also be asked to answer a set of true/false/don't know knowledge items on the method's features derived from the Guttmacher Institute's Survey of Young Adults ("Fogzone" survey) and National Survey of Reproductive and Contraceptive Knowledge, as well as an item on the relative effectiveness of the method in relation to birth control pills. | 3 months and 9 months post-enrollment | |
Secondary | Positive attitudes towards LARC method among primary participants | Self-reported global attitudinal scales in primary participant baseline and follow-up surveys, scored from 0-10. | 3 months and 9 months post-enrollment | |
Secondary | Pregnancy among primary participants | Self-reported measure of interval pregnancy (standardized OAH measure) in primary participant follow-up surveys. | 3 months and 9 months post-enrollment | |
Secondary | Risk of unintended pregnancy | Participants' risky sexual activity, defined as reporting sex without a contraceptive method in the past 3 months. Self-reported in primary and secondary participants' baseline and follow-up surveys. Will include sub-analysis of both primary and secondary participants. | 3 months and 9 months post-enrollment | |
Secondary | Alcohol use | Participants' days of alcohol use as reported in surveys, measured via self-report in measure derived from the Youth Risk Behavior Survey. | 3 months and 9 months post-enrollment | |
Secondary | Knowledge of binge-drinking behaviors | Participants' knowledge of what constitutes binge drinking, including sex differences in binge drinking. Knowledge measures on follow-up surveys will are derived from the youth Risk Behavior survey. | 3 months and 9 months post-enrollment | |
Secondary | Diagnosis of an STI among primary participants | Diagnosis of a sexually transmitted infection (chlamydia, gonorrhea, trichomoniasis [or trich], or other). Measured via self-report in primary participant follow-up surveys (binary yes/no measure of diagnosis, and measure regarding which STI they were diagnosed with). Also assessed via claims data. | 3 months and 9 months post-enrollment | |
Secondary | Acceptability of SpeakOut | Measured using items developed by the researchers to understand participants' experience with and opinion of different intervention components of SpeakOut.. Will be examined among both primary and secondary participants. | 9 months | |
Secondary | Acceptability of PartyWise [control intervention] | Measured using items developed by the researchers to understand participants' experience with and opinion of different intervention components of Party Wise. Will be examined among both primary and secondary participants. | 9 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02577601 -
Impact of Combined Hormonal Contraceptives on UPA
|
Phase 4 | |
Completed |
NCT03153644 -
Improving Contraceptive Care for Women With Medical Conditions
|
||
Completed |
NCT04112095 -
Adherence With Continuous-dose Oral Contraceptive: Evaluation of Self-Selection and Use
|
Phase 3 | |
Recruiting |
NCT05521646 -
Implementing Best Practice Postpartum Contraceptive Services Through a Quality Improvement Initiative
|
N/A | |
Active, not recruiting |
NCT04291001 -
Ovarian Function With ENG Implant and UPA Use
|
Early Phase 1 | |
Completed |
NCT04568980 -
Assessment of Contraceptive Safety and Effectiveness in Cystic Fibrosis
|
||
Completed |
NCT03438682 -
Real World Effectiveness and Safety of Hysteroscopic (Essure®) Compared to Laparoscopic Sterilization
|
||
Active, not recruiting |
NCT01948882 -
Evaluation of Safety and Effectiveness of the Essure (Model ESS505) Device to Prevent Pregnancy in Women
|
N/A | |
Enrolling by invitation |
NCT04997499 -
Adolescent Subcutaneous (SQ) Injection Video Validation
|
N/A | |
Recruiting |
NCT03589040 -
Darunavir and Rilpivirine Interactions With Etonogestrel Contraceptive Implant
|
Phase 2 | |
Completed |
NCT04463680 -
Rifampin and the Contraceptive Implant
|
Phase 4 | |
Completed |
NCT03154125 -
Sayana® Press Extension Study
|
Phase 3 | |
Withdrawn |
NCT03725358 -
A Cluster-RCT to Increase the Uptake of LARCs Among Adolescent Females and Young Women in Cameroon.
|
N/A | |
Completed |
NCT02957630 -
"E4/DRSP Endocrine Function, Metabolic Control and Hemostasis Study"
|
Phase 1/Phase 2 | |
Completed |
NCT02718222 -
Impact and Performance of Institutionalizing Immediate Post-partum IUD Services
|
N/A | |
Completed |
NCT02456584 -
Pharmacodynamics and Pharmacokinetics Study of Existing DMPA Contraceptive Methods
|
Phase 1 | |
Recruiting |
NCT02121067 -
LNG-IUS at 2 Weeks Postpartum
|
Phase 4 | |
Terminated |
NCT02169869 -
Immediate Postplacental IUD Insertion
|
N/A | |
Recruiting |
NCT02292056 -
Medication Safety and Contraceptive Counseling for Reproductive Aged Women With Psychiatric Conditions
|
N/A | |
Withdrawn |
NCT01930994 -
Kenya Sino-implant (II) PK Study
|
N/A |